LEE’S WILL FUND AND MANAGE CHINA CLINICAL SITES FOR JENNEREX’S PIVOTAL PROGRAM AND WILL RETAIN EXCLUSIVE LICENSE RIGHTS IN REGION

San Francisco, California and Hong Kong, November 18, 2009--Jennerex, Inc., a clinical-stage biotherapeutics company developing a proprietary breakthrough class of targeted oncolytic virus therapeutics, today announced in conjunction with Lee’s Pharmaceutical Holdings (HK Stock code: 8221), the execution of a collaboration and license agreement for Jennerex’s lead product candidate, JX-594, in certain Asian territories. Lee’s is a fully integrated pharmaceutical group with operations in People’s Republic of China (PRC), Hong Kong and Macau.